It was a delight to discuss with Anna Moltó (Hospital Cochin, Paris, France) the results of the TICOSPA trial (NCT03043846) which was designed to evaluate the benefit of treat-to-target in patients with axial spondyloarthritis.
The abstract entitled ‘Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial’ (ABSTRACT NUMBER: 1444) was presented at the 2020 ACR Convergence, 5-9 November.
- What are the arguments for and against the treat-to-target (T2T) strategy in the management of axial spondyloarthritis? (0:05)
- Could you tell us a little about the design of the TICOSPA trial? (1:51)
- What were the findings of this study in terms of primary outcomes and safety of the T2T strategy? (2:55)
- What are the implications of these findings for clinical practice? (4:10)
Disclosures: Anna Moltó has acted as a Consultant/Speaker for Abbvie, BMS, Eli Lilly, Novartis, UCB and Gilead.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
Share this Video
Related Videos In Axial Spondyloarthritis
Denis Poddubnyy, ACR 2021: Secukinumab and HLA Subtypes in AxSpA
Prof. Denis Poddubny (Charité-Universitätsmedizin Berlin, Berlin, Germany) kindly took the time to speak with touchIMMUNOLOGY about the post-hoc analysis from the phase 3b SKIPPAIN trial (NCT03136861) aimed at exploring the potential association of HLA-B27 subtypes on the effect of secukinumab in patients with axSpA. This information is brought to you by Touch Medical Media and […]
Inna Gaydukova, EULAR 2021: Netakimab in Patients with Ankylosing Spondylitis with or without Sacroiliitis
It was a pleasure to meet with Professor Inna Gaydukova (North-Western State Medical University, St. Petersburg, Russia) to talk around the changes in ankylosing spondylitis activity in patients with and without sacroiliitis on netakimab treatment. ‘NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY IN PATIENTS WITH OR WITHOUT SACROILIITS ON MRI: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA […]
Peter Taylor, EULAR 2021: Highlights from the Congress
We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the highlights of this year’s EULAR meeting? (0:11) Disclosures: Peter C Taylor reports receiving: Research grants […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!